“ICMR DISAVOWS BHU STUDY ON COVAXIN, CITES CRITICAL FLAWS”
Why in the news? The ICMR disassociated from a BHU study on Covaxin, citing no financial or technical support and critical design flaws. ICMR criticized the study for lacking a control group and proper documentation of adverse events. Source:IndiaToday Key Points about COVAXIN: “COVAXIN is India’s first indigenous COVID-19 vaccine developed by Bharat Biotech in …
Read More